Apr 27, 2020
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC(TM) ODT in the Middle East
Sep 10, 2019
Biohaven Advances NOJECTION(TM) Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
Aug 07, 2019
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
May 07, 2019
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
Apr 01, 2019
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
Feb 04, 2019
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist
Dec 04, 2018
Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.
Nov 20, 2018
Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018
Nov 15, 2018
Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant
Nov 14, 2018
Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results
Oct 22, 2018
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist
Sep 12, 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
Sep 06, 2018
Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine
Aug 14, 2018
Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results
Jun 28, 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Jun 05, 2018
Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018
May 15, 2018
Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results
Apr 19, 2018
Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles
Mar 12, 2018
Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors
Mar 06, 2018
Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine